Hims & Hers launches generic semaglutide in Canada at $149 monthly
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
May 21, 2026 9:00 AM EDTBy introducing access to generic semaglutide in Canada, the company is meeting the needs of a dynamic market and continuing its international expansion efforts
SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers first international generic GLP-1 offering, demonstrating the companys ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at... More
